Market Research Industry Reports

Hypotension - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Hypotension - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H2 2018, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is required for patients with signs and symptoms.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hypotension - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and IND/CTA Filed stages are 1, 1, 1, 2 and 1 respectively.

Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypotension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypotension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypotension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypotension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypotension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypotension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypotension - Overview
Hypotension - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypotension - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypotension - Companies Involved in Therapeutics Development
BCO Pharma Ltd
Cerecor Inc
La Jolla Pharmaceutical Company
Theravance Biopharma Inc
TrioxBio Inc
Hypotension - Drug Profiles
angiotensin II acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dopamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rislenemdaz - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-9855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypotension - Dormant Projects
Hypotension - Product Development Milestones
Featured News & Press Releases
May 29, 2018: TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
Feb 09, 2015: La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Jul 08, 2014: La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension
Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
Nov 03, 2008: Chelsea Therapeutics Reports Significant Reduction In Severity Of Symptoms During Titration Phase Of Pivotal Droxidopa Study In Neurogenic Orthostatic Hypotension
Oct 29, 2008: Data From Chelsea Therapeutics Phase III Trial Of Droxidopa in Neurogenic Orthostatic Hypotension To Be Presented At 19th Annual International Symposium On The Autonomic Nervous System
Sep 02, 2008: Chelsea Therapeutics Begins Patient Dosing In Second Pivotal Phase III Trial Of Droxidopa In Neurogenic Orthostatic Hypotension
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Hypotension, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hypotension - Pipeline by BCO Pharma Ltd, H2 2018
Hypotension - Pipeline by Cerecor Inc, H2 2018
Hypotension - Pipeline by La Jolla Pharmaceutical Company, H2 2018
Hypotension - Pipeline by Theravance Biopharma Inc, H2 2018
Hypotension - Pipeline by TrioxBio Inc, H2 2018
Hypotension - Dormant Projects, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Hypotension, H2 2018 7
Number of Products under Development by Companies, H2 2018 8
Number of Products by Targets, H2 2018 10
Number of Products by Stage and Targets, H2 2018 10
Number of Products by Mechanism of Actions, H2 2018 12
Number of Products by Stage and Mechanism of Actions, H2 2018 12
Number of Products by Routes of Administration, H2 2018 14
Number of Products by Stage and Routes of Administration, H2 2018 14
Number of Products by Molecule Types, H2 2018 16
Number of Products by Stage and Molecule Types, H2 2018 16

Hypotension - Pipeline Review, H2 2018

Hypotension - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H2 2018, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.Low

USD 2000View Report

Orthostatic Hypotension Global Clinical Trials Review, H1, 2018

Orthostatic Hypotension Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Orthostatic Hypotension Global Clinical Trials Review, H1, 2018 provides an overview of Orthostatic Hypotension clinical trials scenario. This report

USD 2500View Report

Parkinsons Disease - Pipeline Review, H2 2017

Parkinsons Disease - Pipeline Review, H2 2017Latest Pharmaceutical and Healthcare disease pipeline guide Parkinsons Disease - Pipeline Review, H2 2017, provides an overview of the Parkinsons Disease (Central Nervous System)

USD 2500View Report

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Jul 2018
No. of Pages :44
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube